Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY3857210 in osteoarthritis pain
NCT05620563Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in osteoarthritis (OA) comparing 45 mg LY3857210 with Placebo (2 arms). Primary endpoint: Change From Baseline for Average Pain Intensity as Measured by the Numeric Rating Scale at Week 8. Started Nov 2022; status: completed.
02
Drugs
RQ-00466479
03
Conditions
osteoarthritis (OA)
Beyond the preview
Go deeper on NCT05620563.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05620563.